Edition:
United Kingdom

Probi AB (PROB.ST)

PROB.ST on Stockholm Stock Exchange

418.20SEK
5:00pm BST
Change (% chg)

-12.20kr (-2.83%)
Prev Close
430.40kr
Open
428.20kr
Day's High
429.80kr
Day's Low
410.20kr
Volume
18,742
Avg. Vol
14,935
52-wk High
613.00kr
52-wk Low
290.00kr

Chart for

About

Probi AB is a Sweden-based company engaged in the probiotics research and development. The Company’s activities are divided into two business areas: Functional Foods, which focuses on the probiotics application in food in partnership with food companies; and Consumer Healthcares, which develops, commercializes and sells Probi... (more)
No analyst recommendations are available for .

Overall

Beta: 0.54
Market Cap(Mil.): kr5,011.63
Shares Outstanding(Mil.): 11.64
Dividend: --
Yield (%): --

Financials

  PROB.ST Industry Sector
P/E (TTM): 167.66 19.86 39.22
EPS (TTM): 2.57 -- --
ROI: 3.17 10.86 46.80
ROE: 3.18 14.37 54.71

BRIEF-Probi Q1 Net Sales Fall To SEK 119.2 Million

* Q1 OPERATING PROFIT SEK 4.4 MILLION VERSUS SEK 48.7 MILLION YEAR AGO

02 May 2018

BRIEF-Probi: Positive Results Of Probi's Probiotic Supplement

* PROBI ENTERS THE BONE HEALTH AREA - A NEW AREA FOR PROBIOTICS

11 Apr 2018

BRIEF-Probi Signs Long-Term Agreement With Cilag

* HAS SIGNED A LONG-TERM AGREEMENT WITH CILAG, A MEMBER OF THE JOHNSON & JOHNSON FAMILY OF COMPANIES FOR THE DEVELOPMENT OF A PROBIOTIC PRODUCT

22 Mar 2018

BRIEF-Probi Appoints Ole Søgaard Andersen As Interim CEO

* ‍ANNOUNCED APPOINTMENT OF OLE SØGAARD ANDERSEN AS INTERIM CHIEF EXECUTIVE OFFICER, EFFECTIVE IMMEDIATELY.​

14 Mar 2018

BRIEF-Probi: Clinical Trial Confirms Immune Enhancing Impact Of Probi Defendum

* LARGEST CLINICAL TRIAL CONFIRMS THE IMMUNE ENHANCING IMPACT OF PROBI DEFENDUM® AND SHEDS NEW LIGHT ON THE MECHANISM

06 Feb 2018

BRIEF-Probi Signs Agreement For Product Launch In North America

* SIGNED MAJOR AGREEMENT FOR LAUNCH OF FUNCTIONAL FOOD PRODUCT IN NORTH AMERICA

12 Dec 2017

Earnings vs. Estimates